CURATIS N AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more
Market Cap & Net Worth: CURATIS N AG (CURN)
CURATIS N AG (SW:CURN) has a market capitalization of $134.46 Million (CHF123.13 Million) as of March 18, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #38786 globally and #134 in its home market, demonstrating a 36.57% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CURATIS N AG's stock price CHF23.90 by its total outstanding shares 5151693 (5.15 Million).
CURATIS N AG Market Cap History: 2015 to 2026
CURATIS N AG's market capitalization history from 2015 to 2026. Data shows change from $1.01 Billion to $134.46 Million (-17.59% CAGR).
CURATIS N AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CURATIS N AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
10.61x
CURATIS N AG's market cap is 10.61 times its annual revenue
1.01x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.01 Billion | $15.59 Million | -$1.63 Million | 64.65x | N/A |
| 2016 | $756.15 Million | $17.94 Million | -$1.02 Million | 42.14x | N/A |
| 2017 | $756.15 Million | $17.55 Million | -$260.00K | 43.08x | N/A |
| 2018 | $277.26 Million | $16.19 Million | -$762.00K | 17.12x | N/A |
| 2019 | $428.49 Million | $17.30 Million | -$940.00K | 24.76x | N/A |
| 2020 | $2.04 Billion | $4.11 Million | -$16.00K | 496.86x | N/A |
| 2024 | $73.14 Million | $6.90 Million | -$4.34 Million | 10.61x | N/A |
Competitor Companies of CURN by Market Capitalization
Companies near CURATIS N AG in the global market cap rankings as of March 18, 2026.
Key companies related to CURATIS N AG by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
CURATIS N AG Historical Marketcap From 2015 to 2026
Between 2015 and today, CURATIS N AG's market cap moved from $1.01 Billion to $ 134.46 Million, with a yearly change of -17.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF134.46 Million | +99.17% |
| 2025 | CHF67.51 Million | -7.69% |
| 2024 | CHF73.14 Million | +625.45% |
| 2023 | CHF10.08 Million | -96.49% |
| 2022 | CHF287.34 Million | -85.19% |
| 2021 | CHF1.94 Billion | -4.94% |
| 2020 | CHF2.04 Billion | +376.47% |
| 2019 | CHF428.49 Million | +54.55% |
| 2018 | CHF277.26 Million | -63.33% |
| 2017 | CHF756.15 Million | 0.00% |
| 2016 | CHF756.15 Million | -25.00% |
| 2015 | CHF1.01 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of CURATIS N AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $134.46 Million USD |
| MoneyControl | $134.46 Million USD |
| MarketWatch | $134.46 Million USD |
| marketcap.company | $134.46 Million USD |
| Reuters | $134.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.